Multiple sclerosis is a chronic and often disabling disease of the nervous system, affecting about 1 million people worldwide. Even though it has been known for over a hundred years, no cause or cure has yet been discovered—but now there is hope. New therapies have been shown to slow the disease progress in some patients, and the pace of discoveries about the cellular machinery of the brain and spinal cord has accelerated.
This book presents a comprehensive overview of multiple sclerosis today, as researchers seek to understand its processes, develop therapies that will slow or halt the disease and perhaps repair damage, offer relief for specific symptoms, and improve the abilities of MS patients to function in their daily lives.
The panel reviews existing knowledge and identifies key research questions, focusing on:
The committee also discusses ways to build and financially support the MS research enterprise, including a look at challenges inherent in designing clinical trials. This book will be important to MS researchers, research funders, health care advocates for MS research and treatment, and interested patients and their families.
Institute of Medicine. 2001. Multiple Sclerosis: Current Status and Strategies for the Future. Washington, DC: The National Academies Press. https://doi.org/10.17226/10031.
|2 Clinical and Biological Features||29-114|
|3 Characteristics and Management of Major Symptoms||115-176|
|4 Disease Management and Measurement||177-240|
|5 Strategies for Future Research on Disease Mechanisms||241-276|
|6 Future Strategies for Therapies||277-324|
|7 Building and Supporting the Research Enterprise||325-346|
|Appendix A: Committee and Staff Biographies||369-376|
|Appendix B: List of Expert Consultants||377-378|
|Appendix C: Workshop Agendas||379-384|
|Appendix D: Kurtze's Expanded Disability Status Scale||385-386|
|Appendix E: Drugs Used in the Treatment of MS||387-400|
|Appendix F: U.S. Social Security Administration's Criteria for Qualifying as Disabled from MS||401-404|
|Appendix G: Treatments That Have Been Claimed to Be of Benefit in MS||405-412|
The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.